当前位置:SCI论文发表网>SCI期刊>Expert Opinion on Drug Metabolism & Toxicology

Expert Opinion on Drug Metabolism & Toxicology

SCI之家头像
创始人 研老师

期刊基本信息

期刊名称:Expert Opinion on Drug Metabolism & Toxicology

出版国家或地区:ENGLAND

是否OA:No

期刊ISSN:1742-5255

期刊官方网站:http://www.tandfonline.com/loi/iemt20#.V48aFkz9cSQ

期刊投稿网址:https://mc.manuscriptcentral.com/eomt

通讯方式:INFORMA HEALTHCARE, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON, ENGLAND, EC2A 4LQ

涉及的研究方向:医学-生化与分子生物学

出版周期:Bimonthly

出版年份:2005

期刊数据表:

最新中科院JCR分区
大类(学科)
小类(学科)
JCR学科排名
医学
BIOCHEMISTRY & MOLECULAR BIOLOGY(生物化学和分子生物学) 3区 PHARMACOLOGY & PHARMACY(药理学和药剂学) 3区 TOXICOLOGY(毒理学) 3区
126/293 83/261 31/94
最新的影响因子
3.47
最新公布的期刊年发文量
年度总发文量 年度论文发表量 年度综述发表量
108 19 89
总被引频次 3776
特征因子 0.006310

Expert Opinion on Drug Metabolism & Toxicology英文简介:

Advanced drug discovery technologies are yielding a dramatic increase in the number of potential drug candidates. However, optimisation of these compounds is becoming increasingly reliant on absorption, distribution, metabolism and excretion (ADME), and toxicological (Tox) issues, a major bottleneck in the drug discovery process. At least 50% of all drug failures in pharmaceutical research are believed to be due to ADME-Tox considerations. Therefore, the ability to solve the ADME-Tox issues of a drug candidate before clinical testing has become of utmost importance in rendering the drug development process more efficient and cost-effective. Furthermore, the continued study of metabolic, pharmacokinetic and toxicological issues surrounding existing compounds is of great importance in the optimisation of drug regimens and therapeutic strategies. Through systematic review and evaluation, Expert Opinion on Drug Metabolism & Toxicology provides a forum for the commentary and analysis of current and emerging research approaches in the ADME-Tox arena, as well as metabolic, pharmacokinetic and toxicological issues relating to specific drugs or drug classes. The journal contains the following article types: Reviews - cover every aspect of drug metabolism and toxicology including in vitro assays, toxicology screens, in vitro, in vivo and in silico ADME models, and pharmacokinetic studies; Drug Evaluations - assess metabolic, pharmacokinetic and toxicological issues related to a specific drug; Technology Profiles - provide analysis of individual technologies, offering readers a comprehensive overview of the specific technology under review; Perspectives - highlight areas of controversy and debate within the field; Meeting Highlights - provide coverage of recent related conferences; Editorials - cover important issues pertaining to drug metabolism and toxicology. The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and related professionals.

Expert Opinion on Drug Metabolism & Toxicology中文简介:

先进的药物发现技术正在使潜在的候选药物数量急剧增加。然而,这些化合物的优化越来越依赖于吸收、分布、代谢和排泄(ADME)以及毒理学(TOX)问题,这是药物发现过程中的一个主要瓶颈。在药物研究中,至少50%的药物失败被认为是由于ADME的毒性考虑。因此,在临床试验前解决药物候选药物的ADME毒性问题的能力,对于提高药物开发过程的效率和成本效益至关重要。此外,继续研究现有化合物周围的代谢、药代动力学和毒理学问题,对于优化药物方案和治疗策略具有重要意义。通过系统的审查和评估,药物代谢和毒理学专家意见提供了一个论坛,用于评论和分析ADME毒理学领域当前和新出现的研究方法,以及与特定药物或药物类别相关的代谢、药代动力学和毒理学问题。该期刊包含以下文章类型:综述----涵盖药物代谢和毒理学的各个方面,包括体外化验、体外、体内和体内的毒理学筛选,以及药物动力学研究;药物评价----评估代谢,与某一特定药物有关的药代动力学和毒理学问题;技术简介----提供对个别技术的分析,使读者全面了解所审查的具体技术;观点----突出该领域内的争议和辩论领域;会议要点----报道最近的相关会议;社论----涉及与药物代谢和毒理学有关的重要问题。听众包括保健和制药行业的科学家和管理人员、学术制药科学家和相关专业人员。

CiteScore历年趋势图

Expert Opinion on Drug Metabolism & Toxicology在线问答:

© http://www.scizj.com/sci/22507.html
SCI之家介绍

SCI之家专业从事SCI期刊、SSCI期刊、EI源刊、SCOPUS期刊、论文咨询服务。SCI之家有来自美国、新加坡、马来西亚的专业英文母语化编审指导团队为您提供专业的英文论文母语润色服务。专注国际学术咨询服务,我们是认真的!

期刊投稿咨询

最新SCI问答 >
关注:453+
2025-04-29 17:04:53
关注:546+
2025-04-28 17:04:14
关注:590+
2025-04-28 17:04:02
关注:512+
2025-04-27 17:04:53
热门SCI问答 >
关注:750+
2025-04-22 17:04:25
关注:590+
2025-04-28 17:04:02
关注:546+
2025-04-28 17:04:14
关注:527+
2025-04-25 17:04:35
EI期刊百问 >
关注:701+
2025-04-12 16:04:03
关注:568+
2025-02-21 17:02:38
关注:504+
2025-02-16 17:02:00
SCOPUS知识>
关注:585+
2025-01-14 17:01:30
关注:659+
2024-10-28 16:10:34
关注:781+
2024-04-22 17:04:35
关注:741+
2024-02-19 17:02:15
关注:800+
2024-01-15 17:01:08
关注:435+
2024-01-12 17:01:11